

Nobivac Myxo-RHD Plus (--)- Lyophilisate and solvent for suspension for injection

Authorised

- Myxoma virus, strain 009, expressing capsid protein gene of Rabbit haemorrhagic disease virus, Live
- Myxoma virus, strain MK1899, expressing capsid protein gene of Rabbit haemorrhagic disease virus 2, Live

Product identification

Medicine name:

Nobivac Myxo-RHD Plus (--)- Lyophilisate and solvent for suspension for injection

Active substance:

Myxoma virus, strain 009, expressing capsid protein gene of Rabbit haemorrhagic disease virus, Live

Myxoma virus, strain MK1899, expressing capsid protein gene of Rabbit haemorrhagic disease virus 2, Live

Target species:

Rabbit

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Myxoma virus, strain 009, expressing capsid protein gene of Rabbit haemorrhagic disease virus, Live

Presentation_strength: $\geq 10^{3.0}$ and $\leq 10^{5.8}$ FFU Comments: 2.c.2.1 Index: 0

Myxoma virus, strain MK1899, expressing capsid protein gene of Rabbit haemorrhagic disease virus 2, Live

Presentation_strength: $\geq 10^{3.0}$ and $\leq 10^{5.8}$ FFU Comments: 2.c.2.1 Index: 1

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

-

Rabbit

- Not applicable. 0 day
Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI08AD

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Belgium , Czechia , Denmark , Finland , France , Germany , Greece , Hungary , Ireland , Italy , Luxembourg , Netherlands , Poland , Portugal , Slovakia , Spain ,

Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Lyophilisate: vial (glass) and solvent: vial (glass),

Package_size:Lyophilisate: 25 vials, solvent: 25 vials, Content:Lyophilisate: 1 dose, solvent: 0.5 ml

Packaging:Lyophilisate: vial (glass) and solvent: vial (glass),

Package_size:Lyophilisate: 10 vials, solvent: 10 vials, Content:Lyophilisate: 50 doses, solvent: 10 ml

Packaging:Lyophilisate: vial (glass) and solvent: vial (glass),

Package_size:Lyophilisate: 5 vials, solvent: 5 vials, Content:Lyophilisate: 1 dose, solvent: 0.5 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Intervet International B.V.

Marketing authorisation date:

19/11/2019

Manufacturing sites for batch release:

Intervet International B.V.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

19/11/2019

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 9/01/2024

[Download](#)

ema-puar-nobivac-myxo-rhd-plus-v-4989-par-en.pdf